A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-177 zadavotide guraxetan (Primary) ; Abiraterone; Enzalutamide; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ECLIPSE
Sponsors Curium Pharma

13 Nov 2024 Primary endpoint (Radiographic Progression Free Survival) has been met, according to Results present in the Curium Pharma Media Release.
13 Nov 2024 Results present in the Curium Pharma Media Release.
31 Oct 2024 Planned End Date changed from 1 Jun 2029 to 1 Feb 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com